Akari is a clinical-stage biopharmaceutical company focused on developing inhibitors of acute and chronic inflammation, specifically the complement system, the eicosanoid system and the bioamine system.
Akari molecules are derived from ticks, where 300 million years of evolution has generated molecules which are well tolerated and target the human inflammatory system with exceptionally tight binding.
24 West 40th Street. 8th Floor
New York, NY, 10018
75/76 Wimpole Street
London W1G 9RT